Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
about
Statins for primary prevention of venous thromboembolismStatins for the primary prevention of cardiovascular diseaseStatins for primary prevention of venous thromboembolismRosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspectiveStatin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP?C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection StudyFrom C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for AtheroprotectionThe influence of innate and adaptive immune responses on atherosclerosisRole of lipotoxicity in endothelial dysfunctionThe role of statins in the setting of HIV infectionPediatric Statin Administration: Navigating a Frontier with Limited DataApplying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the futureReverse Epidemiology of Traditional Cardiovascular Risk Factors in the Geriatric PopulationCRP in cardiovascular diseaseStatin-associated polymyalgia rheumatica. An analysis using WHO global individual case safety database: a case/non-case approachTrends in Statin Use in Seniors 1999 to 2013: Time Series AnalysisIs Sudden Hearing Loss Associated with Atherosclerosis?Imaging atherosclerosis and vulnerable plaque.Can you trust your animal study data?Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration.Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health AdministrationAre markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?Measuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice?The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.Effects of antisense oligonucleotides against C-reactive protein on the development of atherosclerosis in WHHL rabbits.Lovastatin inhibits oxidized L-A-phosphatidylcholine B-arachidonoyl-gamma-palmitoyl (ox-PAPC)-stimulated interleukin-8 mRNA and protein synthesis in human aortic endothelial cells by depleting stores of geranylgeranyl pyrophosphate.Effects of lifestyle measures, antiobesity agents, and bariatric surgery on serological markers of inflammation in obese patients.Inflammation in atherosclerosis: from pathophysiology to practiceEffect of the rs2259816 polymorphism in the HNF1A gene on circulating levels of c-reactive protein and coronary artery disease (the ludwigshafen risk and cardiovascular health study).Impact of metformin on C-reactive protein levels in women with polycystic ovary syndrome: a meta-analysis.Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects.Effects of atorvastatin on human C-reactive protein metabolism.Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients.Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjectsPeripheral arterial tonometry for risk stratification in men with coronary artery diseaseAssociation of salivary lysozyme and C-reactive protein with metabolic syndromeVarespladib methyl in cardiovascular disease.Anti-inflammatory therapies for cardiovascular diseaseNew therapeutic targets for the antiphospholipid syndrome.
P2860
Q24187238-BBFB4AB7-8B3A-4827-924E-49514511594DQ24201513-53423186-469C-40AD-8865-CDE1A835EBADQ24204040-98C0BA98-4F82-49A7-AF52-D22D5A69ABDEQ24594814-A987FE9F-0727-40D8-8360-00153E48ECB2Q24602803-3CA183CF-7B31-4336-992B-814172AB2CBFQ24617734-B979AC2A-74D9-4D51-B902-2BAF4B76DD8BQ26770209-6084C8BB-D866-4154-8A8C-AFC363D12195Q27000370-737AD261-1B59-4DD4-982A-DD74CDBB4EE3Q27000731-5F17DC67-7569-4C31-838E-17C19D2428C1Q27027724-12D58D94-6350-48AB-87B2-DFECA51AE5B2Q28068014-C787E9A4-4504-460E-B589-E741DDE4D2F9Q28074451-7B8F57A6-A34F-4B3E-B4B6-4C53178E7766Q28081914-3BD6E391-A226-4C40-B7AA-3605029C1C28Q28268282-911DA910-C54D-4FEC-8829-BDFFC896F88BQ28481469-872F483C-9C05-4ECD-9CCB-6D318B336C60Q28552707-153AE912-E3B7-4424-8C5E-1787D3419D2AQ30378924-C22228BD-648F-4C1E-86F5-D106462080E3Q30435383-C5074292-77AE-4092-B525-429FCC1B239BQ30829341-C0FBE439-667C-43C8-BEC7-C42D3E279D1BQ30870962-DA9FFEBD-2083-4FBF-9AD8-23A890D2ADAEQ30885473-7901D8B1-5C6B-40F0-A57B-381E0AFA419DQ33474334-6F04A165-62A7-4DCB-A46E-544148068EF4Q33528966-14B7774D-7449-4B50-ADDC-5850E7BE5B24Q33571213-1FE6A4CC-3E58-4FEA-994A-A14422B7D68CQ33607457-CCAB5F7F-EB63-4CE0-BE6E-4E468536AFF3Q33618639-713509F3-CDFA-413B-846C-2B3C00817BF7Q33708384-85423F72-087C-40D8-9991-38EFB36B230CQ33709505-C5ED7361-4A2D-419E-836C-F4969ECD4A51Q33742763-83C19D8C-59ED-4F2E-AD6F-2F02D7EDB2FEQ33798881-7DE88566-01B9-4F82-A836-169919EC46E5Q33831184-121DC7D3-D025-4D80-A986-1F475CEA67D8Q33848035-00BF0BDA-B8A6-4335-B481-48C287543153Q33963850-6E615204-7478-48C7-B7D5-994F32B1FB82Q33972551-E122FBFC-EE4A-4BFC-96E2-505EABDC411AQ33986458-7B072A1C-F150-4D54-B5E4-B4208F70E62EQ34038387-C6FD1182-3D8C-4CEE-8EC7-5B2021CBED0EQ34071936-904D2BE2-385F-4389-AFC0-A3879856D80FQ34135420-C06CE57E-4030-4433-B651-A9867A6BE46AQ34137872-1CDE8CA7-525A-4D7F-A786-CA75D062A364Q34140319-C1E16226-5976-45E8-89FA-A1832D8AAE04
P2860
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Reduction in C-reactive protei ...... ve study of the JUPITER trial.
@en
type
label
Reduction in C-reactive protei ...... ve study of the JUPITER trial.
@en
prefLabel
Reduction in C-reactive protei ...... ve study of the JUPITER trial.
@en
P2093
P50
P1433
P1476
Reduction in C-reactive protei ...... ve study of the JUPITER trial.
@en
P2093
Alberto J Lorenzatti
Antonio M Gotto
Eleanor Danielson
Francisco Ah Fonseca
JUPITER Trial Study Group
Jacques Genest
James Shepherd
James T Willerson
Jean G Macfadyen
John Jp Kastelein
P304
P356
10.1016/S0140-6736(09)60447-5
P407
P577
2009-03-28T00:00:00Z